Edmonton, AB – Dina Kao, a gastroentologist at the University of Alberta Hospital and an associate professor in the Faculty of Medicine & Dentistry’s Department of Medicine, is one of a handful of people in Canada, and just two in Alberta, testing the use of fecal microbial transplant to treat a variety of diseases. The results, she says, recalling one patient she treated for inflammatory bowel disease (IBD), have been nothing short of incredible. “With just one treatment we were able to get him into remission,” she says. “He had complete healing of his bowel. It was amazing.”
“This is the ultimate in bench to bedside research,” says Joyce Mallman Law, president of the University Hospital Foundation, a funder of Kao’s work. “The University Hospital Foundation is proud to partner with Alberta Health Services, the University of Alberta Hospital and the University’s Faculty of Medicine & Dentistry to support new and innovative research that is literally saving lives.”
Fecal microbial transplant involves the transplant of fecal matter from a host to a patient. The aim is to replace and replenish bacteria in the gut microbiome, which researchers now know are key contributors to overall health and are generally beneficial, keeping many diseases in check. Often in those suffering illness, the community of bacteria, or microbiome, has been severely compromised and reduced by the very thing being prescribed to help patients get better—antibiotics.
“We have trillions of bacteria in our gut. There are probably anywhere between 3,000-5,000 different species of bacteria in our gut; it’s that diversity that maintains our health,” says Kao. “It’s just like in the rainforest. If you have just two or three different kinds of species, it’s an unhealthy forest and very unstable.”
While fecal microbial transplant is considered at the leading edge of medical research today, the idea has actually been around for hundreds of years. According to Kao, the first recorded fecal transplant was in fourth century China. In the 1700’s veterinarians used the procedure to treat sick animals. Only in recent years though has serious medical research begun examining it.
“We are still lagging behind but we are slowly picking up,” says Kao.
The most accepted current use of fecal transplant is in the treatment of recurring clostridium difficile infection, or RCDI. But Kao says there is growing belief it could also have applications in treating inflammatory bowel disease (IBD), obesity and even autism. While Kao has put most of her efforts into using fecal transplant to treat c-difficile patients, her latest research, recently published in the Journal of Clinical Gastroentology, shows the procedure has great promise in treatment of IBD.
Part of the work highlighted in the paper shows the rapid recovery of a young man with Crohn’s colitis whom Kao is treating. “We gave him fecal transplant and then within a week his symptoms started to improve.” She adds the real shock came at the follow-up colonoscopy four weeks later for another transplant, as the symptoms had disappeared entirely from his bowel. “I was absolutely shocked to see that the inflammation had completely healed. I wasn’t expecting it to look like that.”
Kao says unlike with RCDI, where one fecal transplant can permanently cure most patients, it appears ongoing treatments are necessary in order to keep IBD from flaring up again. The treatments can be delivered in a number of ways, including an enema, colonoscopy, a feeding tube into the stomach and possibly, one day, in pill form.
Kao credits professor Karen Madsen in the Department of Gastroenterology for helping get the research off the ground. Madsen’s lab, she says, processed all the fecal transplants and stored samples for Kao when she was just starting out with no funding. Since beginning her work with fecal transplants in October of 2012, Kao says she has treated more than 100 RCDI and a handful of IBD patients. She hopes to soon expand her research efforts to look at its use in treating obesity as well. A clinical trial also began in Alberta at the end of September, testing the efficacy of fecal pills in treating RCDI compared to a colonoscopy.
Research funding was provided through a University Hospital Foundation research grant and Alberta Health Services.